ArticleEuropean journal of translational myology2025
OZOILE
Article in European journal of translational myology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ozonides extravirgin olive oil as an alternative to steroids in controlling proliferative behavior in penile lichen sclerosus: a comparative study in pediatric population.Pediatric surgery international · 2025Article
- Long-term monitoring needed for lichen sclerosus.Canadian family physician Medecin de famille canadien · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dear Editor, I would like to express my sincere appreciation for the publication and detailed discussion of therapies for dermatological and inflammatory conditions, as exemplified in the recent article "Onychocryptosis: a retrospective study of clinical aspects, inflammation treatment, and pain management using Ozoile as a hydrogel and cream formulation" by Vincenzo Francavilla et al. This insightful study has provided a comprehensive overview of the management of onychocryptosis, a common and often distressing condition, and has highlighted the innovative use of OZOILE® in a clinical setting.1 [...].
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.